RDR Alert®

The findings can lead to an alternative pain option for patients with sickle cell disease.

The approval is based on findings from a phase 2 clinical trial.

Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.

The FDA approved the CBD solution following the results of a randomized, double-blind, placebo-controlled trial.

The pandemic has burdened blood drives nationally. A new sickle cell drug keeps patients from needing as many transfusions.

How has the new agent fared in its indicated patients in its first year on the market?

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

How a decades-long issue has resulted in at-need patients lacking confident, available physicians.

The findings suggest cannabis should be further investigated as an alternative to opioids.

The 8-7 decision allows Mallinckrodt to move forward with a Sept. 12 PDUFA date for the investigational agent.

A study shows surveyed patients were nearly twice as likely to be satisfied with the care they receive from a usual clinician than an emergency caregiver.

A streamlined testing procedure in sub-Saharan Africa shows improved infant and newborn patient identification.

The findings emphasize that single embryo transfer and singleton births should be encouraged worldwide.

A look at the risks patients face due to the pandemic—and what minority patients may face daily.

A look at the quarter of available drugs for the rare disease, and how they fare in relation to evolving understanding of disease effect.

Triheptanoin is a highly purified, synthetic, seven-carbon fatty triglyceride designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for those with LC-FAOD.

The approval is based on data from 2 randomized, double-blinded, placebo-controlled phase 3 trials.

After promising early findings for the investigative therapy in a rare form of blindness, investigators turn to the next phase.

Ken Ataga, MD, discusses new developments in interpreting the condition's progression and effect on patients.

Crysvita received approval from the FDA for treatment of TIO in patients aged 2 years and older.

A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.

A look at how the rare pulmonary disease field of research has been limited.

The indication is just the second for a therapy treating the rare autoimmune disease.

A look at the appropriate referral and promising agents for care of the rare pulmonary disease.